info@ijrst.com

+919555269393

Track Article

Upload Article

IJRST
About
About IJRST Editorial Board Reviewers Advisory Board Call for Papers Subject Areas Indexing
For Author
Peer Review Guidelines Instruction for Authors Submission Process Manuscript Withdrawal Article Processing Charge Invitation for Reviewers Review Process Article Workflow
Policies
Open Access Policy Review Policy Publication Ethics Article Correction Policy Plagiarism Policy Conflict of Interest Policy
Archive
Past Issues Current Issue
Download
Paper Template Copyright Form Cover Page AIU Prospectus
Certificate FAQ Contact Upload Article Track Article

Details

An Update on the Management of Urinary Tract Infections in the Era of Microbial Resistance

Dina Suhail M Saleh

High Diplom Pharmacology University Al Yarmuk, College of Pharmacy, Iraq

8-15

Vol: 10, Issue: 2, 2020

Receiving Date: 2020-01-15 Acceptance Date:

2020-02-17

Publication Date:

2020-04-16

Download PDF

http://doi.org/10.37648/ijrst.v10i02.002

Abstract

Urinary tract infections (UTIs) caused by antibiotic-resistant Gram-negative bacteria are a growing concern due to limited therapeutic options. Gram-negative bacteria, specifically Enterobacteriaceae, are common causes of both community-acquired and hospital acquired UTIs. These organisms can acquire genes that encode for multiple antibiotic resistance mechanisms, including extended-spectrum-lactamases (ESBLs), AmpC- β -lactamase, and carbapenems. The assessment of suspected UTI includes identification of characteristic symptoms or signs, urinalysis, dipstick or microscopic tests, and urine culture if indicated. UTIs are categorized according to location (upper versus lower urinary tract) and severity (uncomplicated versus complicated). Increasing rates of antibiotic resistance necessitate judicious use of antibiotics through the application of antimicrobial stewardship principles. Knowledge of the common causative pathogens of UTIs including local susceptibility patterns are essential in determining appropriate empiric therapy. The recommended first-line empiric therapies for acute uncomplicated bacterial cystitis in otherwise healthy adult nonpregnant females is a 5-day course of nitrofurantoin or a 3-g single dose of Fosfomycin tromethamine. Second-line options include fluoroquinolones and β-lactams, such as amoxicillin-clavulanate. Current treatment options for UTIs due to AmpC- β -lactamase-producing organisms include Fosfomycin, nitrofurantoin, fluoroquinolones, cefepime, piperacillin-tazobactam and carbapenems. In addition, treatment options for UTIs due to ESBLs-producing Enterobacteriaceae include nitrofurantoin, Fosfomycin, fluoroquinolones, cefoxitin, piperacillin-tazobactam, carbapenems, ceftazidime-avibactam, ceftolozane-tazobactam, and aminoglycosides. Based on identification and susceptibility results, alternatives to carbapenems may be used to treat mild-moderate UTIs caused by ESBL-producing Enterobacteriaceae. Ceftazidime-avibactam, colistin, polymyxin B, Fosfomycin, aztreonam, aminoglycosides, and tigecycline are treatment options for UTIs caused by carbapenem-resistant Enterobacteriaceae (CRE). Treatment options for UTIs caused by multidrug resistant (MDR)-Pseudomonas spp. include fluoroquinolones, ceftazidime, cefepime, piperacillin-tazobactam, carbapenems, aminoglycosides, colistin, ceftazidime-avibactam, and cefdaloxime-tazobactam. The use of fluoroquinolones for empiric treatment of UTIs should be restricted due to increased rates of resistance. Aminoglycosides, colistin, and tigecycline are considered alternatives in the setting of MDR Gram-negative infections in patients with limited therapeutic options.

Keywords: Antibiotic resistance; Enterobacteriaceae; Gram-negative bacteria; cystitis; pyelonephritis; urinary tract infections

References

  1. Peach BC, Garvan GJ, Garvan CS, Cimiotti JP. Risk Factors for Urosepsis in Older Adults: A Systematic Review. Gerontol Geriatr Med. 2016;2:2333721416638980-.
  2. Lane DR, Takhar SS. Diagnosis and management of urinary tract infection and pyelonephritis. Emerg Med Clin North Am. 2011;29(3):539-52
  3. Franco AV. Recurrent urinary tract infections. Best Pract Res Clin Obstet Gynaecol. 2005;19(6):861-73.
  4. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269-84.
  5. Linton AD. Introduction to medical-surgical nursing: Elsevier Health Sciences; 2015.
  6. Colgan R, Williams M, Johnson JR. Diagnosis and treatment of acute pyelonephritis in women. American family physician. 2011;84(5):519.
  7. Salvatore S, Salvatore S, Cattoni E, Siesto G, Serati M, Sorice P, et al. Urinary tract infections in women. European journal of obstetrics & gynecology and reproductive biology. 2011;156(2):131-6.
  8. Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, et al. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs. 2019;79(3):271-89.
  9. Nace DA, Perera SK, Hanlon JT, Saracco S, Anderson G, Schweon SJ, et al. The Improving Outcomes of UTI Management in Long-Term Care Project (IOU) Consensus Guidelines for the Diagnosis of Uncomplicated Cystitis in Nursing Home Residents. J Am Med Dir Assoc. 2018;19(9):765-9.e3.
  10. Woodford HJ, George J. Diagnosis and management of urinary infections in older people. Clinical medicine. 2011;11(1):80-3.
  11. Trestioreanu AZ, Green H, Paul M, Yaphe J, Leibovici L. Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane database of systematic reviews. 2010(10).
  12. Jarvis TR, Chan L, Gottlieb T. Assessment and management of lower urinary tract infection in adults. Aust Prescr. 2014;37:7-9.
  13. Nicolle LE. Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. Urol Clin North Am. 2008;35(1):1-12, v.
  14. Hassan MHA. Effect of intervention guidelines on self care practices of pregnant women with urinary tract infection. Life Science Journal. 2015;12(1):113-24.
  15. Kassim K, Khalaf Z, Abdulhassan A, Salman N. Prevalence and Antibiotic Resistance of Bacteria Isolated from Urinary Tract Infections of Pregnant Women in Baghdad Hospitals. Biomedical and Pharmacology Journal. 2018;11:1989-94
  16. Schaechter M, Medoff G, Eisenstein BI. Mechanisms of microbial disease: Lippincott Williams & Wilkins; 1993.
  17. Salmani H, Azarnezhad A, Fayazi MR, Hosseini A. Pathotypic and Phylogenetic Study of Diarrheagenic Escherichia coli and Uropathogenic E. coli Using Multiplex Polymerase Chain Reaction. Jundishapur J Microbiol. 2016;9(2):e28331.
  18. Shah C, Baral R, Bartaula B, Shrestha LB. Virulence factors of uropathogenic Escherichia coli (UPEC) and correlation with antimicrobial resistance. BMC Microbiology. 2019;19(1):204.
  19. Al-Naqshbandi AA, Chawsheen MA, Abdulqader HH. Prevalence and antimicrobial susceptibility of bacterial pathogens isolated from urine specimens received in rizgary hospital - Erbil. J Infect Public Health. 2019;12(3):330-6.
  20. Hassan KI, Abdullah SR. Detection of Pseudomonas aeruginosa in Clinical Samples Using PCR Targeting ETA and gyrB Genes. Baghdad Science Journal. 2018;15(4):401-5.
  21. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1-14.
  22. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014;6:25-64.
  23. Ramirez MS, Tolmasky ME. Amikacin: Uses, Resistance, and Prospects for Inhibition. Molecules. 2017;22(12):2267.
  24. Kraemer SA, Ramachandran A, Perron GG. Antibiotic Pollution in the Environment: From Microbial Ecology to Public Policy. Microorganisms. 2019;7(6):180.
  25. Li B, Webster TJ. Bacteria antibiotic resistance: New challenges and opportunities for implant-associated orthopedic infections. J Orthop Res. 2018;36(1):22-32.
  26. Opperman E. Cranberry is not effective for the prevention or treatment of urinary tract infections in individuals with spinal cord injury. Spinal cord. 2010;48(6):451
Back

Disclaimer: All papers published in IJRST will be indexed on Google Search Engine as per their policy.

We are one of the best in the field of watches and we take care of the needs of our customers and produce replica watches of very good quality as per their demands.

Our Head Office

Aryavart International University
Mission Tilla, Dharmanagar, North Tripura, India

+91-9555269393

info@ijrst.com

Quick Links

Plagiarism Policy Current Issue Certificate Reviewers FAQs Our Journals

Indexing

© IJRST, All Right Reserved.

Designed By Krrypto